Bill Snyder Archive — Page 40 of 121
-
October 5, 2021
AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC
Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19. -
October 1, 2021
VUMC research contributed to first COVID-19 pill now under review
Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19. -
September 29, 2021
Neurotransmitter transporters expert Amara set for Oct. 7 Discovery Lecture
Susan Amara, PhD, scientific director of the Intramural Research Program at the NIMH and an expert on the biology of neurotransmitter transporters, will deliver Vanderbilt's next Discovery Lecture via Zoom at 4 p.m., Thursday, Oct. 7. -
September 22, 2021
“Ultra-potent” antibody against COVID-19 variants isolated at VUMC
A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. -
September 16, 2021
VUMC team to test personalized acute heart failure treatment
Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure. -
September 16, 2021
Chung receives early investigator award from ASCPT
Vanderbilt's Cecilia Chung, MD, MPH, has received the 2022 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics (ASCPT).